Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.56 |
| ▸ | BRAF | P15056 | 3/20 | 0.56 |
| ▸ | EGFR | P00533 | 3/20 | 0.56 |
| ▸ | FLT3 | P36888 | 1/20 | 0.49 |
| ▸ | EHMT2 | Q96KQ7 | 8/20 | 0.47 |
| ▸ | EHMT1 | Q9H9B1 | 5/20 | 0.47 |
| ▸ | WHR1 | P49842 | 1/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.44 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | LCK | P06239 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4126197 | 0.92 | KDR (0.57) | KDRBRAFEGFRFLT3EHMT2 | |
| SCHEMBL4121881 | 0.89 | BRAF (0.67) | KDRBRAFEGFRFLT3MAPK14 | |
| SCHEMBL4270423 | 0.88 | EGFR (0.53) | KDRBRAFEGFRFLT3EHMT2 | |
| SCHEMBL424206 | 0.82 | BRAF (0.55) | KDRBRAFEGFRFLT3EHMT2 | |
| SCHEMBL4113865 | 0.80 | TP53 (0.59) | KDRBRAFEGFREHMT2EHMT1 | |
| SCHEMBL426756 | 0.80 | BRAF (0.56) | KDRBRAFEGFRFLT3EHMT2 | |
| SCHEMBL458720 | 0.79 | EGFR (0.57) | KDRBRAFEGFRFLT3EHMT2 | |
| SCHEMBL426005 | 0.79 | EGFR (0.57) | KDRBRAFEGFRFLT3EHMT2 | |
| SCHEMBL429163 | 0.79 | KDM4E (0.49) | KDRBRAFEGFRKDM4EALDH1A1 | |
| SCHEMBL428748 | 0.79 | BRAF (0.55) | KDRBRAFEGFRFLT3PDGFRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090253694-A1 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORP. (US) | 2009-10-08 | — | — | US | claimed |
| EP-1687002-A4 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS CORP (US) | 2008-07-23 | — | — | EP | claimed |
| JP-2007510745-A | — | — | 2007-04-26 | — | — | JP | claimed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | claimed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | claimed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | claimed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP (US) | 2015-06-25 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-8318730-B2 | Fused hetrocyclic compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2012-11-27 | — | — | US | disclosed |
| US-20120021434-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | SYNTA PHARMACEUTICALS CORP. (US) | 2012-01-26 | — | — | US | disclosed |
| WO-2007100759-A2 | METHOD FOR TREATING COMMON VARIABLE IMMUNODEFICIENCY | SYNTA PHARMACEUTICALS CORP. (US) | 2007-09-07 | — | — | WO | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | SYNTA PHARMACEUTICALS CORP. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1687002-A1 | FUSED HETEROCYCLIC COMPOUNDS | Synta Pharmaceuticals Corporation (US) | 2006-08-09 | — | — | EP | disclosed |
| US-20050250770-A1 | Fused heterocyclic compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2005-11-10 | — | — | US | disclosed |
| WO-2005046698-A1 | FUSED HETEROCYCLIC COMPOUNDS | SYNTA PHARMACEUTICALS, CORP. (US) | 2005-05-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250770-A1 | Fused heterocyclic compounds | IL2, IL4, IL15 | KDR 3240/4885BRAF 3320/4885EGFR 2725/4885 |
| US-20090253694-A1 | Fused hetrocyclic compounds | IL2, IL15, IL4 | KDR 3480/4885BRAF 4124/4885EGFR 3409/4885 |
| US-20150174132-A1 | METHOD FOR TREATING B CELL REGULATED AUTOIMMUNE DISORDERS | REL, NFATC1, BCL6 | KDR 4489/4885BRAF 892/4885EGFR 4490/4885 |
| US-20070032493-A1 | Method for treating B cell regulated autoimmune disorders | REL, NFATC1, BCL6 | KDR 4489/4885BRAF 892/4885EGFR 4490/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.